Laura Panjwani

Articles

Less Treatment May Show Greater Benefit in Low-Risk Breast Cancer

July 27th 2016

Although there has been in increase in promising novel regimens available for patients with breast cancer in recent years, oncologists should carefully consider whether each agent would provide a significant enough benefit to offset its associated toxicities, cost, and the time and commitment by the patient it requires.

Novel Agents Emerging in Pipeline for HER2+ Breast Cancer

July 20th 2016

Denise A. Yardley, MD, discusses two novel agents on the horizon for HER2-positive breast cancer.

Immunotherapy/Chemo Combinations Show Potential in NSCLC

July 19th 2016

Shirish Gadgeel, MD, discusses the KEYNOTE-021 and KEYNOTE-189 studies, which are both examining pembrolizumab with chemotherapy in patients with non–small cell lung cancer.

Expert Enthusiastic About Immunotherapy in SCLC

July 18th 2016

Raffaele Califano, MD, discusses the KEYNOTE-028 and CheckMate-032 trials, the role of PD-L1 as a biomarker in small cell lung cancer, and what is on the horizon for immunotherapies in the landscape of SCLC.

Immunotherapy Potential Continues to Grow in Gastric Cancers

July 14th 2016

Hendrik-Tobias Arkenau, MD, PhD, discusses the significance of the JAVELIN results for gastrointestinal cancer, the potential for CTLA-4 and PD-1/PD-L1 combinations, and the promise of pembrolizumab (Keytruda) in colorectal cancer.

Survival Outcomes Affected by Tumor Location in KRAS Wild-Type mCRC

July 12th 2016

The debate between the phase III CALGB/SWOG 80405 and FIRE-3 studies has been settled, as findings of a retrospective analysis of 80405 show that tumor location is significant in determining survival outcomes for patients with KRAS wild-type metastatic colorectal cancer.

Expert: Don't Abandon Use of ASCT for Myeloma in 'Novel-Agent Era'

July 11th 2016

Michele Cavo, MD, provides insight on the results of the randomized phase III European Myeloma Network EMN02/HO95 MM trial for multiple myeloma.

FDA Approves First HPV Test for Use With SurePath Preservative Fluid

July 8th 2016

The FDA has approved the cobas HPV Test for use with SurePath Preservative Fluid for the detection of human papilloma virus (HPV) in cervical cells.

FDA Releases Draft Guidances on Next-Generation Sequencing

July 7th 2016

The FDA has issued two draft guidances that will provide regulatory oversight for the use of next-generation sequencing-based tests.

Shore Shares Insight on Challenges of Bone Metastases in mCRPC

July 6th 2016

Bone metastases in castration-resistant prostate cancer create a significant problem, and a rising incidence of men are developing advanced disease.

Phase III Nelipepimut-S Study in Breast Cancer Halted After Futility Review

June 30th 2016

A phase III trial investigating the first-in-class immunotherapy vaccine nelipepimut-S (NeuVax) for the prevention of recurrence in early-stage breast cancer has been stopped due to futility.

KEYNOTE-012 Investigator Explains Promise of Pembrolizumab in HNSCC

June 29th 2016

Ranee Mehra, MD, discusses what the KEYNOTE-012 findings could mean for patients, the growing role for the immunotherapy agent in head and neck cancer, and what else is on the horizon for the treatment landscape.

Hedgehog Agents Advance Basal Cell Carcinoma Care, New Approaches Also Explored

June 27th 2016

Morganna Freeman, DO, explains the impact of hedgehog inhibitors in basal cell carcinoma, the ideal patient to receive them, and emerging agents on the horizon for treatment of the disease.

Expert Highlights Treatment Options for Advanced Basal Cell Carcinoma

June 25th 2016

Ryan J. Sullivan, MD, discusses which patients are at risk for advanced basal cell carcinoma, current standard therapies, and options for those who relapse after treatment with hedgehog/smoothened inhibitors.

B-Cell Receptor Inhibition Paints a Complex Picture in CLL

June 24th 2016

Francesco Forconi, MD, discusses his research into the B-cell receptor structure and its function in chronic lymphocytic leukemia.

Factors Predict Patients Fit for Full 6 Cycles of Radium-223 in mCRPC

June 22nd 2016

In metastatic castration-resistant prostate cancer, pain and hemoglobin levels, PSA levels, and ECOG performance status may predict which patients will be able to receive the recommended 6-dose regimen of radium-223 dichloride (Xofigo).

Safety, Survival Advantages of Radium-223 Continue to Offer Benefit in mCRPC

June 21st 2016

Richard G. Stock, MD, discusses the ideal patient for radium-223 dichloride (Xofigo), its proper sequencing with metastatic castration-resistant prostate cancer, and the future outlook for the therapy.

Expert Discusses Long-Term Survival, Next Steps With Nivolumab in RCC

June 15th 2016

David F. McDermott, MD, provides further insight on the long-term efficacy and safety of nivolumab and its role in renal cell carcinoma, as well as potential combination regimens and challenges with sequencing nivolumab.

Inotuzumab Ozogamicin Improves Outcomes in Relapsed/Refractory ALL

June 13th 2016

Inotuzumab ozogamicin demonstrated significantly improved progression-free survival and complete remission rates compared with chemotherapy for patients with relapsed or refractory acute lymphoblastic leukemia.

Long-Term COMFORT-I Data Confirm Ruxolitinib Survival Benefit

June 12th 2016

Final 5-year efficacy and safety data from the phase III COMFORT-I trial confirm previous findings that ruxolitinib confers a significant benefit in patients with intermediate-2 and high-risk myelofibrosis.